Angelini Labopharm Announces the U.S. Launch of OLEPTRO™ for the Treatment of Major Depressive Disorder in Adults

Tuesday, August 10, 2010 Mental Health News
Email Print This Page Comment
Font : A-A+

OLEPTRO™ Now Available as a New Treatment Option for MDD

For Media Inquiries (Angelini Labopharm)

For Labopharm Investor Relations Inquiries

Michael Parks

Lawrence Chamberlain

Vox Medica, Inc.

Investor Relations

Tel: (267) 885-3066

Tel:  (416) 815-0700

mparks@voxmedica.com

lchamberlain@equicomgroup.com

For Media Inquiries (Angelini)

Fabio Pieroni

Angelini Corporate Communications Director

Tel: +39 06 78053366

f.pieroni@angelini.it



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook